X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/04/16/2863401/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2024.html
https://www.fiercepharma.com/pharma/gsk-details-blenrep-combo-data-could-bring-multiple-myeloma-adc-back-life
https://www.prnewswire.com/news-releases/johnson--johnson-submits-supplemental-biologics-license-application-to-us-fda-seeking-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-for-the-treatment-of-patients-with-transplant-eligible-newly-302048440.html
https://www.prnewswire.com/news-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-therapy-regimen-shows-significant-improvement-in-outcomes-for-patients-with-transplant-eligible-newly-diagnosed-multiple-myeloma-302012983.html
https://www.fiercepharma.com/pharma/jjs-darzalex-sanofis-sarclisa-square-newly-diagnosed-multiple-myeloma-one-unprecedented
https://www.fiercepharma.com/pharma/abbvies-humira-takes-back-its-top-spot-icers-annual-list-unsupported-price-hikes
https://www.onclive.com/view/cd38-48-upregulation-with-tazemetostat-may-overcome-daratumumab-resistance-in-multiple-myeloma
https://www.onclive.com/view/daratumumab-based-quadruplets-show-consistent-efficacy-in-newly-diagnosed-myeloma-despite-early-relapse-in-select-subsets
https://www.globenewswire.com/news-release/2023/07/20/2708002/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-Second-Quarter-of-2023.html
https://www.fiercepharma.com/pharma/johnson-johnsons-darzalex-continues-its-upward-trajectory-company-boosts-2023-revenue
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036
https://www.globenewswire.com//news-release/2022/12/12/2572095/0/en/Janssen-Presents-Efficacy-and-Subgroup-Analyses-from-MAIA-Study-Showing-Long-Term-Results-of-DARZALEX-daratumumab-based-Regimen-in-Newly-Diagnosed-Transplant-Ineligible-Multiple-My.html
https://www.prnewswire.com/news-releases/janssen-presents-efficacy-and-subgroup-analyses-from-maia-study-showing-long-term-results-of-darzalex-daratumumab-based-regimen-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-301700443.html
https://www.prnewswire.com/news-releases/janssen-presents-new-data-for-talquetamab-a-first-in-class-gprc5dxcd3-bispecific-antibody-suggesting-durable-responses-in-patients-with-heavily-pretreated-multiple-myeloma-301699753.html
https://www.globenewswire.com/news-release/2022/12/10/2571405/0/en/Janssen-Presents-First-Data-from-MajesTEC-2-Trial-of-TECVAYLI-teclistamab-in-Combination-with-DARZALEX-daratumumab-Subcutaneous-SC-Formulation-and-Lenalidomide-in-Relapsed-or-Refra.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036
https://www.clinicaltrialsarena.com/news/janssen-trial-multiple-myeloma/
http://www.pharmafile.com/news/721160/smc-accepts-first-licensed-treatment-newly-diagnosed-al-amyloidosis
https://www.fiercepharma.com/pharma/jjs-switch-iv-subcutaneous-darzalex-85-complete-us
https://www.globenewswire.com/news-release/2022/04/19/2424195/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2022.html
https://www.fiercepharma.com/pharma/jj-scores-one-two-royalty-punch-against-genmab-megablockbuster-darzalex-arbitration
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036
https://www.globenewswire.com/news-release/2022/01/25/2372309/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-2021.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761036
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761145
http://www.pharmafile.com/news/600992/nice-recommends-combination-treatment-patients-multiple-myeloma
https://www.prnewswire.com/news-releases/halozyme-announces-janssen-receives-us-fda-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-combination-with-carfilzomib-and-dexamethasone-for-patients-with-multiple-myeloma-after-first-or-subsequent-relapse-301435510.html
https://www.pharmaceutical-technology.com/news/jj-split-consumer-health-pharmaceutical/
https://www.evaluate.com/vantage/articles/news/deals/non-genetic-amyloidosis-lives-again-thanks-darzalex-and-astra
https://www.fiercepharma.com/pharma/nice-rejects-j-j-s-darzalex-combo-regimen-for-newly-diagnosed-myeloma-but-leaves-negotiation
http://www.pharmafile.com/news/586557/nice-rejects-combination-treatment-multiple-myeloma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma
https://www.globenewswire.com/news-release/2021/06/22/2251169/0/en/Genmab-Announces-that-Janssen-has-Received-European-Marketing-Authorizations-for-DARZALEX-daratumumab-Subcutaneous-Formulation-Including-for-the-Treatment-of-Patients-with-Newly-Di.html
https://www.prnewswire.com/news-releases/halozyme-announces-janssen-receives-european-marketing-authorizations-for-darzalex-daratumumab-subcutaneous-formulation-for-newly-diagnosed-systemic-light-chain-amyloidosis-and-pre-treated-multiple-myeloma-301317659.html
https://www.businesswire.com/news/home/20210612005027/en/%C2%A0Janssen-Announces-Results-from-Phase-3-MAIA-Study-Showing-Significant-Overall-Survival-Benefits-for-Treatment-with-DARZALEX%C2%AE%E2%96%BC-daratumumab-in-Patients-with-Newly-Diagnosed-Multiple-Myeloma-Who-are-Transplant-Ineligible
https://www.prnewswire.com/news-releases/european-hematology-association---daratumumab-maintenance-improves-progression-free-survival-after-autologous-stem-cell-transplantation-in-multiple-myeloma-patients-301308008.html
https://www.prnewswire.com/news-releases/european-hematology-association-overall-survival-benefit-established-with-daratumumab-plus-lenalidomide-and-dexamethasone-d-rd-in-elderly-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma-ndmm-long-term-in-301310175.html
https://www.prnewswire.com/news-releases/janssen-announces-results-from-phase-3-maia-study-showing-significant-overall-survival-benefits-for-treatment-with-darzalex-daratumumab-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible-301311235.html
https://www.prnewswire.com/news-releases/updated-data-demonstrate-significant-improvement-in-hematologic-complete-response-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-in-patients-with-newly-diagnosed-light-chain-al-amyloidosis-301299846.html
https://www.prnewswire.com/news-releases/halozyme-announces-janssen-receives-two-positive-chmp-opinions-for-darzalex-daratumumab-subcutaneous-formulation-utilizing-enhanze-301296932.html
https://www.onclive.com/view/subcutaneous-daratumumab-plus-vcd-approved-in-canada-for-newly-diagnosed-light-chain-amyloidosis
https://www.fiercepharma.com/marketing/sanofi-s-sarclisa-forays-into-j-j-s-darzalex-new-territory-fda-nod-for-earlier-multiple
https://www.globenewswire.com/news-release/2021/01/26/2164095/0/en/Genmab-Announces-2020-Net-Sales-of-DARZALEX-daratumumab.html
Market Place
Share 
